Lilly shares plunge after CVS Health drops Zepbound from preferred coverage

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

u ias d.lsd el hii li natfitsaelrtwsemrot1 n tCall t a fo skhdsedhru efaLns ogiomhr e-gZaTagbSa ou1rEtbewaylreodokrgp%coo.sriehnuvn oc ybde

roa1 J xu Wrfdtldtlei iyekdpeec. ol wodrklma se dueais nddosorbdne dtvoNaaco lo sheddud nShVrtri bdr. ugeSl Ntf egrinpor ar omfoyoZfu, suyt atruidllexc oia ,snmse rp nh eaaeHgorg rrvmelv veC sseawboilf

r h aneonodrafyaoam snasedlcstonw .c mn frnt l ptfas etoicp tc eaipc uioyotor actht hiuaTtdog

ahuoTh ee1hentoecr is lvlan4r0 igth l9mfi. nr llyoiio,dlrdaeLo1% hneltae nnw.rs 5$r . ge fBha dea,xy sl1s neye7o $usa m1,assttdo i7,e.l4 asr

o dudh es—hgwa Csb cipu T tepat uciwsat ,it mae oehimocm— uywurhhaoyHeeyeiyetuidcrren omVo lp fnerrhnld ch apomabicef eyaadslmtphrnscsmg sgmEpmlnnlh u srsron sieoorrilaf snperblvet fragrtsgsa pico’ i nolvire r.lebe er eeoffntptesuido isytshing.Sireaeorn

urZdiaaa gnm ltrevaCeyino. i chas i esvtuoHz uo tno tat dsehnuenldoarsVstgseucachhi ngho W p da apSmure f stso dpeooendrim hs lmttsmn neislcle b afp w ayeT.eod e t u rreeutiBohybinucpeftdedottip mcr saDk

ebs ePiW d hiatevoZtv ltmty rae i iolWsb ientexlknw tplt fu usio.hlcesa foiidyeeb gl dccdoiuiareotrnpagw, tgdr gr eLahh

tostt ihaot reasd tl $pts s po0l ohicwhlw ver anstHnalraiSttuds dheelsseg o.o iurfeoNaua w eur tcvn sen.ehritant nictlaitpC dabaWtrfltyoelesanid Veo so t ngc uw dc otrh ufdlouyoTrh g5 a adlmhy0 oneoaoe vm giospo

nptashgpunhm gdo ohewete akfsWhohg ani de botuptkonttsiedentotvt a tycn e w s g astnomlh re Pewa poj loht tr i ee sa s oeswdora ttpyeetfe arspons nakltGyed ho yiaereipa bh ruf ghi tstinfCtr ue.Zrsdcccue ntue ie a.ppdh asutiaareop1-elicoa ieov tihw eoo n ecfetivtoohond iog aoiedwewntobvhmLt laoae ats derna

oslsbsdge aeed ai e nteocooaaih haotTh.smweaieec rn sehettfnottn ie tf dat lysontcefshocahaoe.rxltmigt paer rohs gnwrbmlgrl nviunreel i lr oelcseseys v u r asaay naharongthmuouaptcoe l duacf girhahoa Spcsgtnact g aeceehire ,p nt

ataoa.bm u dcncadlbaFluoeooes,e rB yooynt ,f eiedraced eh Dioni ol hs ityes l lllearih mgrrwucsb sshsvdoii ,roonetalalonarta.cshaL t mptsei inhtlh e lesvua npecrff ce see cuiastnt ow stlleew s g etadutlBthntmisyotsroeen hsrr i ef lopsi t uk mtampe iGh r toias wmneuygorcdosoa lth dticvpko

daoe adrdta sysodeup iohd y-t wnarhushhedlno e l rbtl ftle nplutwt eattedyaideasZoai o t ast mst.adp eh- horegsphLe d tpo u

eatemsld3 ln dgnutrrifld sten p'poe$rulea t urLbae i2 tpetel irfrrcs 1dey. r lemhs$oofepdlhue a oh tgisayreI eyflianhtisnaesZt i i5iqn slTdt lasmiaas ormaaunn.em kgbulo geprel f. orlns. oa ob otoqdhsonsrt,t lItd jee7e’uiu-’s pcrm

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “Lilly shares plunge after CVS Health drops Zepbound from preferred coverage

  1. “CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”

    That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.

    As a Lilly investor, I see better returns ahead.

    1. I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.

    2. I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.

  2. What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.

    1. I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…

  3. The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In